Skip to main content
PMC home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1997 Jan;35(1):111–116. doi: 10.1128/jcm.35.1.111-116.1997

Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

R K Straubinger 1, B A Summers 1, Y F Chang 1, M J Appel 1
PMCID: PMC229521  PMID: 8968890

Abstract

In specific-pathogen-free dogs experimentally infected with Borrelia burgdorferi by tick exposure, treatment with high doses of amoxicillin or doxycycline for 30 days diminished but failed to eliminate persistent infection. Although joint disease was prevented or cured in five of five amoxicillin- and five of six doxycycline-treated dogs, skin punch biopsies and multiple tissues from necropsy samples remained PCR positive and B. burgdorferi was isolated from one amoxicillin- and two doxycycline-treated dogs following antibiotic treatment. In contrast, B. burgdorferi was isolated from six of six untreated infected control dogs and joint lesions were found in four of these six dogs. Serum antibody levels to B. burgdorferi in all dogs declined after antibiotic treatment. Negative antibody levels were reached in four of six doxycycline- and four of six amoxicillin-treated dogs. However, in dogs that were kept in isolation for 6 months after antibiotic treatment was discontinued, antibody levels began to rise again, presumably in response to proliferation of the surviving pool of spirochetes. Antibody levels in untreated infected control dogs remained high.

Full Text

The Full Text of this article is available as a PDF (1.9 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander A. D., Rule P. L. Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis. Antimicrob Agents Chemother. 1986 Dec;30(6):835–839. doi: 10.1128/aac.30.6.835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alt D. P., Bolin C. A. Preliminary evaluation of antimicrobial agents for treatment of Leptospira interrogans serovar pomona infection in hamsters and swine. Am J Vet Res. 1996 Jan;57(1):59–62. [PubMed] [Google Scholar]
  3. Appel M. J., Allan S., Jacobson R. H., Lauderdale T. L., Chang Y. F., Shin S. J., Thomford J. W., Todhunter R. J., Summers B. A. Experimental Lyme disease in dogs produces arthritis and persistent infection. J Infect Dis. 1993 Mar;167(3):651–664. doi: 10.1093/infdis/167.3.651. [DOI] [PubMed] [Google Scholar]
  4. Baradaran-Dilmaghani R., Stanek G. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics. Infection. 1996 Jan-Feb;24(1):60–63. doi: 10.1007/BF01780660. [DOI] [PubMed] [Google Scholar]
  5. Barthold S. W. Animal models for Lyme disease. Lab Invest. 1995 Feb;72(2):127–130. [PubMed] [Google Scholar]
  6. Bennett J. V., Brodie J. L., Benner E. J., Kirby W. M. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol. 1966 Mar;14(2):170–177. doi: 10.1128/am.14.2.170-177.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dattwyler R. J., Halperin J. J., Pass H., Luft B. J. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis. 1987 Jun;155(6):1322–1325. doi: 10.1093/infdis/155.6.1322. [DOI] [PubMed] [Google Scholar]
  8. Demaerschalck I., Ben Messaoud A., De Kesel M., Hoyois B., Lobet Y., Hoet P., Bigaignon G., Bollen A., Godfroid E. Simultaneous presence of different Borrelia burgdorferi genospecies in biological fluids of Lyme disease patients. J Clin Microbiol. 1995 Mar;33(3):602–608. doi: 10.1128/jcm.33.3.602-608.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Georgilis K., Peacocke M., Klempner M. S. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro. J Infect Dis. 1992 Aug;166(2):440–444. doi: 10.1093/infdis/166.2.440. [DOI] [PubMed] [Google Scholar]
  10. Goodman J. L., Bradley J. F., Ross A. E., Goellner P., Lagus A., Vitale B., Berger B. W., Luger S., Johnson R. C. Bloodstream invasion in early Lyme disease: results from a prospective, controlled, blinded study using the polymerase chain reaction. Am J Med. 1995 Jul;99(1):6–12. doi: 10.1016/s0002-9343(99)80097-7. [DOI] [PubMed] [Google Scholar]
  11. Hassler D., Riedel K., Zorn J., Preac-Mursic V. Pulsed high-dose cefotaxime therapy in refractory Lyme borreliosis. Lancet. 1991 Jul 20;338(8760):193–193. doi: 10.1016/0140-6736(91)90188-u. [DOI] [PubMed] [Google Scholar]
  12. Häupl T., Hahn G., Rittig M., Krause A., Schoerner C., Schönherr U., Kalden J. R., Burmester G. R. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum. 1993 Nov;36(11):1621–1626. doi: 10.1002/art.1780361118. [DOI] [PubMed] [Google Scholar]
  13. Johnson R. C., Kodner C. B., Jurkovich P. J., Collins J. J. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother. 1990 Nov;34(11):2133–2136. doi: 10.1128/aac.34.11.2133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Johnson R. C., Kodner C., Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother. 1987 Feb;31(2):164–167. doi: 10.1128/aac.31.2.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Klempner M. S., Noring R., Rogers R. A. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J Infect Dis. 1993 May;167(5):1074–1081. doi: 10.1093/infdis/167.5.1074. [DOI] [PubMed] [Google Scholar]
  16. Ma Y., Sturrock A., Weis J. J. Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect Immun. 1991 Feb;59(2):671–678. doi: 10.1128/iai.59.2.671-678.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Malawista S. E., Barthold S. W., Persing D. H. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J Infect Dis. 1994 Nov;170(5):1312–1316. doi: 10.1093/infdis/170.5.1312. [DOI] [PubMed] [Google Scholar]
  18. Massarotti E. M., Luger S. W., Rahn D. W., Messner R. P., Wong J. B., Johnson R. C., Steere A. C. Treatment of early Lyme disease. Am J Med. 1992 Apr;92(4):396–403. doi: 10.1016/0002-9343(92)90270-l. [DOI] [PubMed] [Google Scholar]
  19. McClain J. B., Ballou W. R., Harrison S. M., Steinweg D. L. Doxycycline therapy for leptospirosis. Ann Intern Med. 1984 May;100(5):696–698. doi: 10.7326/0003-4819-100-5-696. [DOI] [PubMed] [Google Scholar]
  20. McFadden P. Lyme disease research. Science. 1995 Dec 1;270(5241):1419–1419. [PubMed] [Google Scholar]
  21. Moody K. D., Adams R. L., Barthold S. W. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob Agents Chemother. 1994 Jul;38(7):1567–1572. doi: 10.1128/aac.38.7.1567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Moter S. E., Hofmann H., Wallich R., Simon M. M., Kramer M. D. Detection of Borrelia burgdorferi sensu lato in lesional skin of patients with erythema migrans and acrodermatitis chronica atrophicans by ospA-specific PCR. J Clin Microbiol. 1994 Dec;32(12):2980–2988. doi: 10.1128/jcm.32.12.2980-2988.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nadelman R. B., Nowakowski J., Forseter G., Bittker S., Cooper D., Goldberg N., McKenna D., Wormser G. P. Failure to isolate Borrelia burgdorferi after antimicrobial therapy in culture-documented Lyme borreliosis associated with erythema migrans: report of a prospective study. Am J Med. 1993 Jun;94(6):583–588. doi: 10.1016/0002-9343(93)90208-7. [DOI] [PubMed] [Google Scholar]
  24. Nowakowski J., Nadelman R. B., Forseter G., McKenna D., Wormser G. P. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):223–227. doi: 10.1016/0190-9622(95)90130-2. [DOI] [PubMed] [Google Scholar]
  25. Panconesi E., Zuccati G., Cantini A. Treatment of syphilis: a short critical review. Sex Transm Dis. 1981 Oct-Dec;8(4 Suppl):321–325. [PubMed] [Google Scholar]
  26. Persing D. H., Rutledge B. J., Rys P. N., Podzorski D. S., Mitchell P. D., Reed K. D., Liu B., Fikrig E., Malawista S. E. Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J Infect Dis. 1994 Mar;169(3):668–672. doi: 10.1093/infdis/169.3.668. [DOI] [PubMed] [Google Scholar]
  27. Preac Mursic V., Patsouris E., Wilske B., Reinhardt S., Gross B., Mehraein P. Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals. A comparison with histopathological findings in human Lyme disease. Infection. 1990 Nov-Dec;18(6):332–341. doi: 10.1007/BF01646399. [DOI] [PubMed] [Google Scholar]
  28. Preac-Mursic V., Weber K., Pfister H. W., Wilske B., Gross B., Baumann A., Prokop J. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection. 1989 Nov-Dec;17(6):355–359. doi: 10.1007/BF01645543. [DOI] [PubMed] [Google Scholar]
  29. Preac-Mursic V., Wilske B., Schierz G., Süss E., Gross B. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi. Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651–653. doi: 10.1007/BF01968150. [DOI] [PubMed] [Google Scholar]
  30. Rahn D. W. Antibiotic treatment of Lyme disease. Current recommendations by stage and extent of infection. Postgrad Med. 1992 May 15;91(7):57–64. doi: 10.1080/00325481.1992.11701343. [DOI] [PubMed] [Google Scholar]
  31. Rijpkema S. G., Molkenboer M. J., Schouls L. M., Jongejan F., Schellekens J. F. Simultaneous detection and genotyping of three genomic groups of Borrelia burgdorferi sensu lato in Dutch Ixodes ricinus ticks by characterization of the amplified intergenic spacer region between 5S and 23S rRNA genes. J Clin Microbiol. 1995 Dec;33(12):3091–3095. doi: 10.1128/jcm.33.12.3091-3095.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sadziene A., Jonsson M., Bergström S., Bright R. K., Kennedy R. C., Barbour A. G. A bactericidal antibody to Borrelia burgdorferi is directed against a variable region of the OspB protein. Infect Immun. 1994 May;62(5):2037–2045. doi: 10.1128/iai.62.5.2037-2045.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sambri V., Armati S., Cevenini R. Animal and human antibodies reactive with the outer surface protein A and B of Borrelia burgdorferi are borreliacidal, in vitro, in the presence of complement. FEMS Immunol Med Microbiol. 1993 Jun;7(1):67–71. doi: 10.1111/j.1574-695X.1993.tb00383.x. [DOI] [PubMed] [Google Scholar]
  34. Schmidli J., Hunziker T., Moesli P., Schaad U. B. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J Infect Dis. 1988 Oct;158(4):905–906. doi: 10.1093/infdis/158.4.905. [DOI] [PubMed] [Google Scholar]
  35. Schwartz I., Wormser G. P., Schwartz J. J., Cooper D., Weissensee P., Gazumyan A., Zimmermann E., Goldberg N. S., Bittker S., Campbell G. L. Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J Clin Microbiol. 1992 Dec;30(12):3082–3088. doi: 10.1128/jcm.30.12.3082-3088.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Shadick N. A., Phillips C. B., Logigian E. L., Steere A. C., Kaplan R. F., Berardi V. P., Duray P. H., Larson M. G., Wright E. A., Ginsburg K. S. The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med. 1994 Oct 15;121(8):560–567. doi: 10.7326/0003-4819-121-8-199410150-00002. [DOI] [PubMed] [Google Scholar]
  37. Sigal L. H. Current recommendations for the treatment of Lyme disease. Drugs. 1992 May;43(5):683–699. doi: 10.2165/00003495-199243050-00005. [DOI] [PubMed] [Google Scholar]
  38. Sigal L. H. Persisting symptoms of Lyme disease--possible explanations and implications for treatment. J Rheumatol. 1994 Apr;21(4):593–595. [PubMed] [Google Scholar]
  39. Steere A. C. Lyme disease. N Engl J Med. 1989 Aug 31;321(9):586–596. doi: 10.1056/NEJM198908313210906. [DOI] [PubMed] [Google Scholar]
  40. Straubinger R. K., Chang Y. F., Jacobson R. H., Appel M. J. Sera from OspA-vaccinated dogs, but not those from tick-infected dogs, inhibit in vitro growth of Borrelia burgdorferi. J Clin Microbiol. 1995 Oct;33(10):2745–2751. doi: 10.1128/jcm.33.10.2745-2751.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Strle F., Preac-Mursic V., Cimperman J., Ruzic E., Maraspin V., Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection. 1993 Mar-Apr;21(2):83–88. doi: 10.1007/BF01710737. [DOI] [PubMed] [Google Scholar]
  42. Wahlberg P., Granlund H., Nyman D., Panelius J., Seppälä I. Treatment of late Lyme borreliosis. J Infect. 1994 Nov;29(3):255–261. doi: 10.1016/s0163-4453(94)91105-3. [DOI] [PubMed] [Google Scholar]
  43. Watt G., Padre L. P., Tuazon M. L., Calubaquib C., Santiago E., Ranoa C. P., Laughlin L. W. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet. 1988 Feb 27;1(8583):433–435. doi: 10.1016/s0140-6736(88)91230-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES